A Fixed-Dose Study of Lamotrigine Versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects With Bipolar I Disorder

Trial Profile

A Fixed-Dose Study of Lamotrigine Versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects With Bipolar I Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Lamotrigine (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Aug 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 20 Aug 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top